1. 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes. (10th December 2020) Authors: Jaderberg, Magnus; Cedres, Susana; Paz-Ares, Luis; Serres, Xavier; Ricordel, Charles; Isambert, Nicolas; Aix, Santiago Ponce; Levitsky, Victor; Kuryk, Lukasz; Moller, Anne-Sophie; Vetrhus, Sylvia Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes. (9th November 2020) Authors: Jaderberg, Magnus; Cedres, Susana; Paz-Ares, Luis; Serres, Xavier; Ricordel, Charles; Isambert, Nicolas; Aix, Santiago Ponce; Levitsky, Victor; Kuryk, Lukasz; Moller, Anne-Sophie; Vetrhus, Sylvia Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A386 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Issue 1 (January 2023) Authors: Aix, Santiago Ponce; Ciuleanu, Tudor Eliade; Navarro, Alejandro; Cousin, Sophie; Bonanno, Laura; Smit, Egbert F; Chiappori, Alberto; Olmedo, Maria Eugenia; Horvath, Ildiko; Grohé, Christian; Farago, Anna F; López-Vilariño, José Antonio; Cullell-Young, Martin; Nieto, Antonio; Vasco, Noelia; Gómez,... Journal: Lancet Issue: Volume 11:Issue 1(2023) Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Issue 5 (May 2017) Authors: Rosell, Rafael; Dafni, Urania; Felip, Enriqueta; Curioni-Fontecedro, Alessandra; Gautschi, Oliver; Peters, Solange; Massutí, Bartomeu; Palmero, Ramon; Aix, Santiago Ponce; Carcereny, Enric; Früh, Martin; Pless, Miklos; Popat, Sanjay; Kotsakis, Athanasios; Cuffe, Sinead; Bidoli, Paolo; Favaretto, ... Journal: Lancet Issue: Volume 5:Issue 5(2017) Page Start: 435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗